 COA |
MSDS |
 HPLC |
NMR |
| CAS No: | 472981-92-3 |
| Molecular formula(MF) | C16H14ClNO2 |
| Molecular Weight(MW): | 287.74 |
| Alias |
| In vitro | DMSO | 57 mg/mL (198.09 mM) |
|---|---|---|
| Water | <1 mg/mL | |
| Ethanol | <1 mg/mL | |
| In vivo |
| Description | SB-366791 is a novel, potent, and selective, cinnamide TRPV1 antagonist. | ||
|---|---|---|---|
| Targets |
|
||
| In vitro |
SB-366791 is a structurally novel and potent TRPV1 antagonist which is capable of inhibiting the capsaicin-, acid- and heat-mediated activation of the receptor but produces little or no effect on a wide range of enzymes, ion channels, GPCRs and other proteins. SB-366791 may prove to be a better tool for unambiguously defining the (patho)physiological role of TRPV1[1]. |
||
| In vivo | the TRPV1 antagonist SB366791 reduces the number of flinches but did not improve ambulation and weight-bearing. A sub-analgesic dose of SB366791 potentiates the effects of morphine at doses of 3.0 and 10.0 mg/kg on flinches and weight-bearing but not ambulation. The combination of morphine and SB366791 has potent analgesic effects on bone cancer pain[2]. |